Abstract
In the EU, the approved use of erlotinib (Tarceva(®)), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations.
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents / therapeutic use
-
Asian People / genetics
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Clinical Trials, Phase III as Topic
-
Epidermal Growth Factor / genetics*
-
Epidermal Growth Factor / metabolism
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Erlotinib Hydrochloride
-
Humans
-
Mutation
-
Practice Guidelines as Topic*
-
Protein Kinase Inhibitors / therapeutic use
-
Quinazolines / therapeutic use*
-
Randomized Controlled Trials as Topic
-
White People / genetics
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Epidermal Growth Factor
-
Erlotinib Hydrochloride
-
ErbB Receptors